Cadence Bank’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cadence Bank’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,077	Closed	-$280K	–	251
2017 Q4	$280K	Buy	+2,077	New	+$288K	0.03%	207

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cadence Bank's JAZZ Position: Q1 2018 in Review

Cadence Bank sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 2,077 shares — an estimated $280K sold.

Cadence Bank first reported a position in JAZZ in Q4 2017 and held it in 1 quarter. The position peaked at $280K in Q4 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

Cadence Bank reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Cadence Bank sold 2,077 Jazz Pharmaceuticals shares in Q1 2018, an estimated $280K.
Cadence Bank first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Cadence Bank's Jazz Pharmaceuticals position peaked at $280K in Q4 2017.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Cadence Bank's 13F filing for Q1 2018, filed 3 May 2018.